Before the market open on the last trading day of the week, two analysts tracking (NASDAQ: GMAB) stock felt compelled to raise their price targets on the biotech. This double-barreled blast of bullishness pushed the company's shares more than 4% higher that trading session, easily beating the essentially stagnant S 500 (SNPINDEX: ^GSPC).

Not surprisingly, both lifts were based largely on Genmab's latest acquisition. On Tuesday, the company announced it struck a deal to acquire Dutch peer Merus in a purchase valued at $8 billion.

Image source: Getty Images.

Continue reading

Source Fool.com